Accessibility Menu
NovAccess Global logo

NovAccess Global(OTC) XSNX

Market Cap$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-100%
1 Year-67%
1 Month+0%
$0.00
+0.00%
+0.00Today
NovAccess Global last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-11
NovAccess Global stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-04
1 month+0%USD 0.002026-07-09
3 month+0%USD 0.002026-05-12
Year to date+0%USD 0.002025-12-31
1 year-66.67%USD 0.002025-08-08
3 year-99.91%USD 0.112023-08-11
5 year-99.98%USD 0.482021-08-12
Since inception-100%USD 35,000.001998-09-18

NovAccess Global Financials at a Glance

Market Cap

$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.89M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-8.12 (Low)

Price

$0.00

Volume

65,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

Oct 29, 2025

XSNX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovAccess Global

NovAccess Global Inc. operates as a biopharmaceutical firm focused on developing innovative immunotherapies for brain tumors. The company leverages cutting-edge research to harness the immune system in targeting and eliminating cancerous cells.

Products and Services
  • Development of immunotherapies for brain tumor treatment
  • Research initiatives aimed at enhancing patient outcomes
  • Collaboration with healthcare professionals for clinical advancements
Growth Outlook
  • Significant potential in the biotechnology sector with increasing demand for cancer therapies
  • Focus on innovative research may lead to breakthrough treatments
  • Partnerships with healthcare institutions could enhance market reach
Financial Highlights
  • Recent quarterly net income of -$936,333 reflects ongoing investment in R&D
  • Trailing twelve months show a consistent focus on developing core technologies
  • Cash and short-term investments totaled $794 as of June 30, 2024
NovAccess Global Inc. is positioned in a rapidly evolving biotechnology landscape, with a commitment to addressing critical healthcare challenges. The company's focus on immunotherapy represents a promising avenue for growth, particularly in the treatment of brain tumors. Despite recent financial challenges, the ongoing investment in research and development underscores a long-term vision aimed at delivering innovative solutions to patients. The potential for partnerships and collaborations within the healthcare sector may further enhance the company's prospects, making it an intriguing option for investors interested in the biotechnology field.
AI Generated • Jul 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Dwain Morris-Irvin, PhD

Website

www.novaccessglobal.com

Headquarters

New York, NY 44026, US

XSNX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

76.60%

Return on Capital

N/A

Return on Assets

-7661.59%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

61.65M

Volume

65.00K

Avg. Volume

1.29K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.22M

EBITDA

-$467.23K

Operating Cash Flow

-$314.83K

Capital Expenditure

$3.00

Free Cash Flow

-$314.82K

Cash & ST Invst.

$794.00

Total Debt

$2.09M

NovAccess Global Performance Analysis

NovAccess Global annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-09-30USD 0N/A
20222022-09-30USD 0N/A
20232023-09-30USD 0N/A
20242024-09-30USD 0N/A
NovAccess Global sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-09-30N/A
Q12023-12-31N/A
Q22024-03-31N/A
Q32024-06-30N/A
NovAccess Global annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-09-30USD -0.22N/A
20222022-09-30USD -0.10-53.5%
20232023-09-30USD -0.23120.6%
20242024-09-30USD -0.06-74.0%
NovAccess Global sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-09-30-120.9%
Q12023-12-31116.7%
Q22024-03-31-227.9%
Q32024-06-30-994152.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.10K

N/A

Employees

2

N/A

Net Income

-$936.33K

-20.1%

EBITDA

-$435.26K

-558125.6%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$794.00

-98.7%

Total Debt

$2.09M

+9.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.09M

+9.8%

Return on Assets

-76.62%

N/A

Return on Invested Capital

31.63%

N/A

Free Cash Flow

-$58.87K

+48.0%

Operating Cash Flow

-$58.87K

+48.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARDSAridis Pharmaceuticals, Inc.
$0.00+0.00%
NNLXNanoLogix, Inc.
$0.00+0.00%
EVLOEvelo Biosciences, Inc.
$0.00+0.00%
TRVNTrevena, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About XSNX

What is the current price of NovAccess Global?

NovAccess Global is trading at $0.00 per share.

What is the 52-week range for NovAccess Global?

Over the past 52 weeks, NovAccess Global has traded between $0.00 and $0.05.

How much debt does NovAccess Global have?

As of the most recent reporting period, NovAccess Global reported total debt of $2.22M.

How much cash does NovAccess Global have on hand?

NovAccess Global reported $20.89K in cash and cash equivalents in its most recent financial results.

What is NovAccess Global’s dividend yield?

NovAccess Global does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services